Graphite Bio Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Graphite Bio (Nasdaq: GRPH), a leader in next-generation gene editing, has announced its participation in two significant investor conferences. CEO Josh Lehrer will speak at the Cowen 2nd Annual Genetic Medicines Summit on February 3, 2022, and engage in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. Both events reflect Graphite Bio's commitment to advancing gene editing technologies aimed at curing serious diseases. The fireside chat will be available for live streaming on the company's website.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced participation in the following upcoming investor conferences:

• Cowen 2^nd Annual Genetic Medicines Summit: Josh Lehrer, M.D., chief executive officer of Graphite Bio, will be a featured speaker on the “Clinical Development Topics: Gene Editing” panel on Thursday, Feb. 3, 2022, at 11 a.m. ET.
• 11^th Annual SVB Leerink Global Healthcare Conference: Fireside chat on Thursday, Feb. 17, 2022, at 1:40 p.m. ET.

The fireside chat will be webcast live from Graphite Bio’s website at www.graphitebio.com in the Investors section. A replay of the webcast will be archived and available following the event.

About Graphite Bio
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

Learn more about Graphite Bio by visiting www.graphitebio.com and following the company on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005171/en/

Company:

Stephanie Yao

VP, Communications and Investor Relations

443-739-1423

syao@graphitebio.com

Investor Relations:

Stephanie Ascher

Stern IR, Inc.

212-362-1200

ir@graphitebio.com

Media:

Joey Fleury

Real Chemistry

415-946-1090

media@graphitebio.com

Source: Graphite Bio, Inc.

FAQ

What events is Graphite Bio participating in February 2022?

Graphite Bio will participate in the Cowen 2nd Annual Genetic Medicines Summit on February 3, 2022, and the SVB Leerink Global Healthcare Conference on February 17, 2022.

Who will represent Graphite Bio at the Cowen Genetic Medicines Summit?

CEO Josh Lehrer will be a featured speaker at the Cowen 2nd Annual Genetic Medicines Summit.

Where can I watch the Graphite Bio fireside chat?

The Graphite Bio fireside chat on February 17, 2022, can be streamed live from their website.

What is the focus of Graphite Bio's gene editing technology?

Graphite Bio focuses on therapies that utilize targeted gene integration to treat or cure serious diseases.

What is the significance of the upcoming conferences for Graphite Bio?

The conferences are significant as they provide a platform for Graphite Bio to share advancements in gene editing and attract investor interest.